Article ; Online: Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience.
Journal of the neurological sciences
2019 Volume 409, Page(s) 116601
Abstract: Lacosamide (LCM) is a new generation antiepileptic drug. It has only been available in Asia in recent years. A retrospective study at two hospitals in Hong Kong was performed to investigate the post-marketing efficacy and tolerability of the drug. A ... ...
Abstract | Lacosamide (LCM) is a new generation antiepileptic drug. It has only been available in Asia in recent years. A retrospective study at two hospitals in Hong Kong was performed to investigate the post-marketing efficacy and tolerability of the drug. A total of 81 subjects were recruited, among which 88% had drug-resistant epilepsy. The most common type of epilepsy was focal with unknown etiology. All patients used LCM as adjunctive therapy. The 50% responder rate was 42% at 12 weeks after achievement of maximal dose of LCM. No specific factor correlated with responsiveness including concomitant enzyme-inducing or sodium channel blocking anticonvulsants. Withdrawal rate within first 12 weeks after drug initiation was 14% while that at any time upon follow-up was 23%. Two cases of uncommon adverse reaction of myoclonus were also reported. The mechanism was postulated to be the sodium channel inhibiting action of LCM. Our study has shown LCM to have comparable efficacy and tolerability in post-marketing experience when compared with the landmark randomized controlled trials. |
---|---|
MeSH term(s) | Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anticonvulsants/administration & dosage ; Child ; Child, Preschool ; Cohort Studies ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Epilepsy/diagnosis ; Epilepsy/drug therapy ; Epilepsy/epidemiology ; Female ; Hong Kong/epidemiology ; Humans ; Lacosamide/administration & dosage ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult |
Chemical Substances | Anticonvulsants ; Lacosamide (563KS2PQY5) |
Language | English |
Publishing date | 2019-11-27 |
Publishing country | Netherlands |
Document type | Journal Article ; Multicenter Study ; Pragmatic Clinical Trial |
ZDB-ID | 80160-4 |
ISSN | 1878-5883 ; 0022-510X ; 0374-8642 |
ISSN (online) | 1878-5883 |
ISSN | 0022-510X ; 0374-8642 |
DOI | 10.1016/j.jns.2019.116601 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 308: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.